Skip to main content
 

Main menu

  • Home
  • Content
    • Current Issue
    • Editor's Commentary
    • Archives
    • Most-Read Papers of 2022
  • Authors
    • Author Guidelines
    • Submit a Manuscript
  • Reviewers
    • Reviewer Information
    • Create Reviewer Account
    • Reviewer Guidelines: Original Research
    • Reviewer Guidelines: Reviews
    • Appreciation of Reviewers
  • CRCE
    • Through the Journal
    • JournalCasts
    • AARC University
    • PowerPoint Template
  • Open Forum
    • 2023 Open Forum
    • 2023 Abstracts
    • Previous Open Forums
  • Podcast
    • English
    • Español
    • Portugûes
    • 国语
  • Videos
    • Video Abstracts
    • Author Interviews
    • The Journal

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
American Association for Respiratory Care
  • Subscribe
  • My alerts
  • Log in
American Association for Respiratory Care

Advanced Search

  • Home
  • Content
    • Current Issue
    • Editor's Commentary
    • Archives
    • Most-Read Papers of 2022
  • Authors
    • Author Guidelines
    • Submit a Manuscript
  • Reviewers
    • Reviewer Information
    • Create Reviewer Account
    • Reviewer Guidelines: Original Research
    • Reviewer Guidelines: Reviews
    • Appreciation of Reviewers
  • CRCE
    • Through the Journal
    • JournalCasts
    • AARC University
    • PowerPoint Template
  • Open Forum
    • 2023 Open Forum
    • 2023 Abstracts
    • Previous Open Forums
  • Podcast
    • English
    • Español
    • Portugûes
    • 国语
  • Videos
    • Video Abstracts
    • Author Interviews
    • The Journal
  • Twitter
  • Facebook
  • YouTube
EditorialEditorials

Aerosolized Antibiotic Therapy: A Forward Aerial Assault or Forced Contingency for Ventilator-Associated Pneumonia?

Molly E Moore and Eric W Mueller
Respiratory Care August 2012, 57 (8) 1348-1349; DOI: https://doi.org/10.4187/respcare.02016
Molly E Moore
Department of Pharmacy Services UC Health-University Hospital Division of Pharmacy Practice University of Cincinnati Cincinnati, Ohio
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric W Mueller
Department of Pharmacy Services UC Health-University Hospital Division of Pharmacy Practice University of Cincinnati Cincinnati, Ohio
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Info & Metrics
  • References
  • PDF
Loading

The increasing prevalence and complexity of multiple-drug-resistant (MDR) organisms in nosocomial infections have fueled interest in novel therapeutic approaches. Adjunctive aerosolized antibiotic (AAA) therapy for pneumonia has gained popularity, supported by apparent advantages of higher pulmonary antibiotic concentrations and lower systemic exposure. Balanced by a paucity of high-level evidence, consensus statements recommend AAA therapy be considered in patients with MDR pathogens not responding to intravenous therapy.1,2

The most commonly reported aerosolized agents, aminoglycosides and colistin, have narrow therapeutic indexes and poor pulmonary penetration3,4 associated with systemic administration. However, these agents often have higher bactericidal potencies and retained in vitro susceptibility against many MDR pathogens (eg, Pseudomonas aeruginosa and Acinetobacter species).5 These qualities, in combination with their concentration-dependent pharmacodynamic properties (ie, the higher the antibiotic concentration to bacterial minimum inhibitory concentration, the greater bacterial killing), make intermittent aerosolization of these agents attractive.

Although there has been some progress in formal aerosolized antibiotic drug development intended for the treatment of pneumonia in critically ill patients,6 prospective studies evaluating the effects on patient outcome have been limited by underpowered design, lack of control group, heterogeneous definitions for pneumonia, variable treatment regimens, poorly described aerosolization methods, and concomitant antibiotic therapy.2 Published meta-analyses nicely frame many of these limitations.7,8 Consequently, most recent reports and series have described the use of aerosolized aminoglycosides or colistin as adjunctive or salvage therapy in patients with pneumonia recurrence or pneumonia caused by MDR pathogens.9–13

In this issue of Respiratory Care, Arnold and colleagues report their AAA experience at a large, urban, academic medical center for the treatment of P. aeruginosa and Acinetobacter ventilator-associated pneumonia (VAP).14 The investigators performed a retrospective cohort study of 93 critically ill medical and surgical patients with clinically defined, microbiologically confirmed VAP who received AAA (n = 19) with colistin 150 mg twice daily (n = 9), or tobramycin 300 mg twice daily (n = 10), or no AAA (n = 74); all patients received intravenous antibiotic therapy. Although these dosages have been used for aerosolization, there are limited data describing the pulmonary pharmacokinetics, including lobular distribution and clearance, in critically ill, mechanically ventilated patients.2,15 Patients receiving AAA therapy had higher Acute Physiology and Chronic Health Evaluation II scores, were more likely to have MDR pathogens, had longer delays in appropriate antimicrobial therapy, and were more likely to receive intravenous aminoglycoside or colistin. Durations of definitive intravenous antibiotic therapy were not statistically different (AAA 17.8 ± 13.3 d vs no AAA 12.8 ± 8.5 d, P = .16), but may have reflected treatment bias toward higher severity of illness and MDR pathogens in AAA patients. Patients receiving AAA had longer durations of mechanical ventilation and associated ICU and hospital stay. Clinical and microbiologic resolution of pneumonia was not evaluated. Despite the apparent differences in severity of illness and appropriate antibiotic therapy, crude 30-day mortality post-VAP diagnosis was lower in the AAA patients (0.0% vs 17.6%, P = .063, P = .03 long-rank test per survival analysis). However, when patients requiring palliative care were included in both groups, there was no difference in crude mortality (32.1% vs 33.3, P = .91).

This study represents the complexity of the limited evidence base supporting aerosolized antibiotic therapy for pneumonia and real-world challenges when using narrow therapeutic index antibiotics in critically ill patients with VAP, in particular, episodes caused by MDR pathogens. The strengths of the study include consistent dosing and administration of AAA, bacteriologically confirmed VAP, and objective patient outcome end points. Limitations include observational, retrospective design; small sample size; inability to assess individual effects of colistin and tobramycin; lack of formal matched control group; and limited information for clinical or microbiologic resolution of pneumonia. The findings related to mortality are not definitive, given the limitations in study design. However, they are compelling, because the clinical scenario of VAP caused by MDR pathogens is increasingly common, and AAA therapy appeared to safely mitigate a higher baseline risk. Interestingly, the addition of palliative care to the mortality assessment brings to light the importance of this disposition in ICU-related outcomes studies, pending standardization and differentiation between palliative and hospice care. Perhaps the most relevant application of this study is the shared experience of a provocative therapeutic strategy in complex critically ill patients with tenuous and potentially perilous infectious circumstances.

With the increasing prevalence of MDR pathogens and dearth of new antibiotics in development, prospective comparative effectiveness studies are needed to establish the utility of alternative administration methods of available agents (eg, prolonged infusion of β-lactams) that optimize antibiotic pharmacodynamic properties while limiting adverse effects. Aerosolization of colistin and aminoglycosides for pneumonia is a relevant pursuit, as limitations in the current evidence base strongly support the need for multicenter randomized controlled prospective trials. Particular focus should include standardization of effective delivery techniques, pharmacokinetic assessment, and the use of AAA as adequate empiric antimicrobial therapy, or even monotherapy, to validate the presumed pharmacokinetic-pharmacodynamic benefits, compared to intravenous administration. In the meantime, it appears that AAA therapy with colistin and aminoglycosides for the treatment of VAP are reasonable options in complex critically ill patients with difficult to treat pathogens and conditions limiting the utility and safety of systemic administration. Amid the ongoing struggle against MDR pathogens in VAP, AAA therapy may be a viable contingency when the improbability for success with conventional antibiotic therapy approaches or exceeds the breaking point.

Footnotes

  • Correspondence: Eric W Mueller PharmD, Department of Pharmacy Services, University of Cincinnati, 234 Goodman Street, ML 0791, Cincinnati OH 45219. E-mail: eric.mueller{at}uchealth.com.
  • The authors have disclosed no conflicts of interest.

  • See the Original Study on Page 1226

  • Copyright © 2012 by Daedalus Enterprises Inc.

References

  1. 1.↵
    American Thoracic Society, Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care 2005;171(4):388–416.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Le J,
    2. Ashley ED,
    3. Neuhauser MM,
    4. Brown J,
    5. Gentry C,
    6. Klepser ME,
    7. Marr AM,
    8. et al
    ; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2010;30(6):562–584.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Imberti R,
    2. Cusato M,
    3. Villani P,
    4. Carnevale L,
    5. Iotti GA,
    6. Langer M,
    7. Regazzi M
    . Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methane sulfonate administration. Chest 2010;138(6):1333–1339.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Panidis D,
    2. Markantonis SL,
    3. Boutzouka E,
    4. Karatzas S,
    5. Baltopoulos G
    . Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005;128(2):545–552.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rhomberg PR,
    2. Fritsche TR,
    3. Sader HS,
    4. Jones RN
    . Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn Microbiol Infect Dis 2006;56(1):57–62.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Luyt CE,
    2. Clavel M,
    3. Guntupalli K,
    4. Johannigman J,
    5. Kennedy JI,
    6. Wood C,
    7. et al
    . Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 2009;13(6):R200.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Ioannidou E,
    2. Siempos II,
    3. Falagas ME
    . Administration of antimicrobials via the respiratory tract of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007;60(6):1216–1226.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Florescu DF,
    2. Qiu F,
    3. McCartan MA,
    4. Mindru C,
    5. Fey PD,
    6. Kalil AC
    . What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-analysis. Clin Infect Dis 2012;54(5):670–680.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Mohr AM,
    2. Sifri ZC,
    3. Horng HS,
    4. Sadek R,
    5. Savetamal A,
    6. Hauser CJ,
    7. Livingston DH
    . Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. Surg Infect 2007;8(3):349–357.
    OpenUrlCrossRef
  10. 10.
    1. Czosnowski QA,
    2. Wood GC,
    3. Magnotti LJ,
    4. Croce MA,
    5. Swanson JM,
    6. Boucher BA,
    7. Fabian TC
    . Adjunctive aerosolized antibiotics for the treatment of ventilator-associated pneumonia. Pharmacother 2009;29(9):1051–1060.
    OpenUrl
  11. 11.
    1. Michalopoulos A,
    2. Fotakis D,
    3. Virtzili S,
    4. Vletsas C,
    5. Raftopoulou S,
    6. Mastora Z,
    7. Falagas ME
    . Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multi-drug resistant Gram-negative bacteria: a prospective study. Respir Med 2008;102(3):407–412.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Kofteridis DP,
    2. Alexopoulou C,
    3. Valachis A,
    4. Maraki S,
    5. Dimopoulou D,
    6. Georgopoulos D,
    7. Samonis G
    . Aerosolized plus intravenous colistin versus intravenous colisitn alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010;51(11):1238–1244.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Michalopoulos A,
    2. Kasiakou SK,
    3. Mastora Z,
    4. Rellos K,
    5. Kapaskelis AM,
    6. Falagas ME
    . Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9(1):R53–59.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Arnold HM,
    2. Sawyer AM,
    3. Kollef MH
    . Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 2012;57(8):1226–1233.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Wood GC,
    2. Swanson JM
    . Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs 2007;67(6):903–914.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Respiratory Care: 57 (8)
Respiratory Care
Vol. 57, Issue 8
1 Aug 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Monthly Podcasts

 

Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Association for Respiratory Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Aerosolized Antibiotic Therapy: A Forward Aerial Assault or Forced Contingency for Ventilator-Associated Pneumonia?
(Your Name) has sent you a message from American Association for Respiratory Care
(Your Name) thought you would like to see the American Association for Respiratory Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Aerosolized Antibiotic Therapy: A Forward Aerial Assault or Forced Contingency for Ventilator-Associated Pneumonia?
Molly E Moore, Eric W Mueller
Respiratory Care Aug 2012, 57 (8) 1348-1349; DOI: 10.4187/respcare.02016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Aerosolized Antibiotic Therapy: A Forward Aerial Assault or Forced Contingency for Ventilator-Associated Pneumonia?
Molly E Moore, Eric W Mueller
Respiratory Care Aug 2012, 57 (8) 1348-1349; DOI: 10.4187/respcare.02016
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

Info For

  • Subscribers
  • Institutions
  • Advertisers

About Us

  • About the Journal
  • Editorial Board

AARC

  • Membership
  • Meetings
  • Clinical Practice Guidelines

More

  • Contact Us
  • RSS
American Association for Respiratory Care

Print ISSN: 0020-1324        Online ISSN: 1943-3654

© Daedalus Enterprises, Inc.

Powered by HighWire